YARW · XBRL financial data

Yarrow Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (YARW's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	135	114	76*	98	198	121	84*	202	69	year only	86	97
Research and development	7,233	3,318	3,023*	3,708	7,306	10,248	9,684*	6,124	4,881	year only	817	788
Selling, general and administrative	3,220	3,030	—	—	—	—	—	—	—	—	—	—
General and administrative	3,220	3,030	3,885*	3,770	3,288	2,964	3,170*	3,275	2,730	year only	3,085	2,411
Operating income (loss)	(10,318)	(6,234)	(6,832)*	(7,380)	(10,396)	(13,091)	(12,770)*	(9,197)	(7,542)	year only	(3,816)	(3,102)
Other income (expense)	280	163	680*	1,139	1,001	934	760*	594	1,795	year only	231	203
Income tax expense (benefit)	0	0	0*	0	0	0	4*	0	0	year only	0	0
Net income (loss)	(10,058)	(6,584)	(6,188)*	(6,249)	(9,406)	(12,157)	(12,022)*	(8,611)	(5,755)	year only	(3,585)	(3,007)
Earnings per share, basic USD per share	(3.09)	(2.01)	—	(0.15)	(0.22)	(0.29)	(0.28)*	(0.20)	(0.13)	—	(0.08)	(3.51)
Earnings per share, diluted USD per share	(3.09)	(2.01)	—	(0.15)	(0.22)	(0.29)	(0.28)*	(0.20)	(0.13)	—	(0.08)	(3.51)
Weighted average shares, basic thousands of shares	3,274	3,282	—	42,581	42,586	42,587	42,602*	42,673	42,759	—	42,768	858
Weighted average shares, diluted thousands of shares	3,274	3,282	—	42,581	42,586	42,587	42,602*	42,673	42,759	—	42,768	858

Balance sheet

CSV

Fiscal quarters (YARW's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	20,634	15,448	30,620	19,065	29,609	16,272	19,926	28,209	22,047	24,027	24,631	22,925
Short-term investments	—	—	62,633	66,885	48,492	53,913	41,590	22,063	17,600	4,981	297	—
Marketable securities	—	—	62,633	66,885	48,492	53,913	41,590	22,063	17,600	4,981	297	0
Accounts receivable	234	250	—	—	—	—	—	—	—	—	—	—
Prepaid and other current assets	2,024	1,759	2,656	4,219	5,629	3,303	2,921	4,641	4,696	1,002	861	601
Total current assets	22,959	17,511	95,963	90,223	83,776	73,535	64,437	54,913	44,343	30,010	25,789	23,526
Property and equipment, net	—	—	0	—	—	—	113	107	102	90	84	78
Right-of-use asset	0	0	207	180	151	122	93	62	32	0	—	—
Total assets	24,959	19,267	97,685	91,676	86,648	76,198	66,905	56,423	44,718	30,160	25,873	23,604
Accrued liabilities	4,379	4,452	4,119	3,642	5,069	6,168	9,272	6,858	3,578	941	889	815
Total current liabilities	6,374	6,449	7,538	6,930	11,754	12,661	14,819	12,291	5,836	2,395	1,236	1,542
Lease liability, non-current	—	—	99	63	25	0	0	—	—	—	—	—
Total liabilities	7,687	7,762	8,950	8,306	11,779	12,661	14,819	12,291	5,836	2,395	1,236	1,542
Accumulated deficit	(678,564)	(685,148)	(691,336)	(697,585)	(706,991)	(719,148)	(731,170)	(739,781)	(745,536)	(757,653)	(761,238)	(764,245)
Total stockholders' equity	17,272	11,505	88,735	83,370	74,869	63,537	52,086	44,132	38,882	27,765	24,637	22,062
Total liabilities and equity	24,959	19,267	97,685	91,676	86,648	76,198	66,905	56,423	44,718	30,160	25,873	23,604
Common shares outstanding (cover page) thousands of shares	3,280	13,957	14,099	14,528	14,749	14,751	15,210	16,665	25,472	33,323	33,353	2,670

Cash flows

CSV

Fiscal quarters (YARW's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(10,058)	(6,584)	(6,188)*	(6,249)	(9,406)	(12,157)	(12,022)*	(8,611)	(5,755)	year only	(3,585)	(3,007)
Stock-based compensation	876*	863*	710*	985	885*	734*	699*	763	529*	year only	474	436*
Depreciation and amortization	0*	0*	0*	0	0*	—	year only	6	6*	year only	6	6*
Net cash from operating activities	(9,574)*	(5,152)*	(5,137)*	(7,982)	(8,481)*	(8,510)*	(8,999)*	(11,461)	(10,803)*	year only	(4,081)	(1,992)*
Net cash from investing activities	0*	0*	(62,354)*	(3,569)	19,020*	(4,824)*	12,738*	19,831	4,675*	year only	4,700	300*
Proceeds from issuing common stock	0*	0*	—	0	0*	0*	—	—	—	—	—	—
Net cash from financing activities	(5)*	(47)*	82,663*	(4)	(3)*	(2)*	(132)*	(87)	(34)*	year only	(15)	(14)*
Net change in cash	(9,579)*	(5,199)*	15,172*	(11,555)	10,536*	(13,336)*	3,607*	8,283	(6,162)*	year only	604	(1,706)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.